Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 5/20 | 0.64 |
| ▸ | PARP2 | Q9UGN5 | 3/20 | 0.64 |
| ▸ | PARP14 | Q460N5 | 14/20 | 0.61 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.61 |
| ▸ | TNKS | O95271 | 3/20 | 0.56 |
| ▸ | TNKS2 | Q9H2K2 | 3/20 | 0.56 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31483817 | 1.00 | PARP1 (0.64) | PARP1PARP2PARP14PARP11TNKS | |
| SCHEMBL31483741 | 0.88 | PARP1 (0.69) | PARP1PARP2PARP14PARP11TNKS | |
| SCHEMBL21072527 | 0.88 | PARP1 (0.69) | PARP1PARP2PARP14PARP11TNKS | |
| SCHEMBL17298080 | 0.86 | PARP1 (0.66) | PARP1PARP2PARP14PARP11TNKS | |
| SCHEMBL24923453 | 0.84 | PARP1 (0.64) | PARP1PARP2PARP14PARP11TNKS | |
| SCHEMBL20355545 | 0.83 | PARP1 (0.71) | PARP1PARP2PARP14PARP11TNKS | |
| SCHEMBL21777220 | 0.83 | PARP14 (0.61) | PARP1PARP2PARP14PARP11 | |
| SCHEMBL30846567 | 0.83 | PARP14 (0.61) | PARP1PARP2PARP14PARP11 | |
| SCHEMBL6928926 | 0.83 | PARP1 (0.62) | PARP1PARP2PARP14PARP11TNKS | |
| SCHEMBL19104695 | 0.82 | PARP1 (0.61) | PARP1PARP2PARP14PARP11TNKS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030858-B2 | PARP inhibitors for treating cancer and asthma | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030858-B2 | PARP inhibitors for treating cancer and asthma | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2024-07-09 | — | — | US | disclosed |
| US-11958837-B2 | Quinazolinones as PARP14 inhibitors | RIBON THERAPEUTICS, INC. (US) | 2024-04-16 | — | — | US | disclosed |
| EP-3843726-B1 | PARP INHIBITORS FOR TREATING CANCER AND ASTHMA | UNIV OREGON HEALTH & SCIENCE (US) | 2024-02-28 | — | — | EP | disclosed |
| EP-4212515-A1 | QUINAZOLINONES AS PARP14 INHIBITORS | Ribon Therapeutics Inc. (US) | 2023-07-19 | — | — | EP | disclosed |
| EP-4212515-A1 | QUINAZOLINONES AS PARP14 INHIBITORS | Ribon Therapeutics Inc. (US) | 2023-07-19 | — | — | EP | disclosed |
| EP-3728207-B1 | QUINAZOLINONES AS PARP14 INHIBITORS | RIBON THERAPEUTICS INC (US) | 2023-02-01 | — | — | EP | disclosed |
| EP-3728207-B1 | QUINAZOLINONES AS PARP14 INHIBITORS | RIBON THERAPEUTICS INC (US) | 2023-02-01 | — | — | EP | disclosed |
| US-20230018702-A1 | QUINAZOLINONES AS PARP14 INHIBITORS | ABBVIE BIOTECHNOLOGY LTD (BM) | 2023-01-19 | — | — | US | disclosed |
| US-20230018702-A1 | QUINAZOLINONES AS PARP14 INHIBITORS | ABBVIE BIOTECHNOLOGY LTD (BM) | 2023-01-19 | — | — | US | disclosed |
| US-20200247788-A1 | QUINAZOLINONES AS PARP14 INHIBITORS | ABBVIE BIOTECHNOLOGY LTD (BM) | 2020-08-06 | — | — | US | disclosed |
| US-20200247788-A1 | QUINAZOLINONES AS PARP14 INHIBITORS | ABBVIE BIOTECHNOLOGY LTD (BM) | 2020-08-06 | — | — | US | disclosed |
| WO-2020046753-A1 | PARP INHIBITORS FOR TREATING CANCER AND ASTHMA | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2020-03-05 | — | — | WO | disclosed |
| US-10562891-B2 | Quinazolinones as PARP14 inhibitors | Ribon Therapeutics Inc. (US) | 2020-02-18 | — | — | US | disclosed |
| US-10562891-B2 | Quinazolinones as PARP14 inhibitors | Ribon Therapeutics Inc. (US) | 2020-02-18 | — | — | US | disclosed |
| US-20190194174-A1 | QUINAZOLINONES AS PARP14 INHIBITORS | ABBVIE BIOTECHNOLOGY LTD (BM) | 2019-06-27 | — | — | US | disclosed |
| US-20190194174-A1 | QUINAZOLINONES AS PARP14 INHIBITORS | ABBVIE BIOTECHNOLOGY LTD (BM) | 2019-06-27 | — | — | US | disclosed |
| CN-103755647-B | C2 bit derivant of 4 (3H)-quinazolinones and its production and use | CAPITAL NORMAL UNIV. (CN) | 2015-12-09 | — | — | CN | disclosed |
| CN-103755647-A | C2-bit derivative of 4(3H)-quinazolinone and preparation method and application thereof | UNIV CAPITAL NORMAL | 2014-04-30 | — | — | CN | disclosed |
| WO-2011012622-A1 | BENZOXAZINONE DERIVATIVES FOR THE TREATMENT OF GLYTL MEDIATED DISORDERS | GLAXO GROUP LIMITED (GB) | 2011-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11958837-B2 | Quinazolinones as PARP14 inhibitors | PARP14, PARP15, PARP11 | PARP1 5/4885PARP2 10/4885PARP14 1/4885 |
| US-20200247788-A1 | QUINAZOLINONES AS PARP14 INHIBITORS | PARP14, PARP15, PARP11 | PARP1 5/4885PARP2 10/4885PARP14 1/4885 |
| US-12030858-B2 | PARP inhibitors for treating cancer and asthma | PARP1, PARP2, PARP11 | PARP1 1/4885PARP2 2/4885PARP14 7/4885 |
| US-10562891-B2 | Quinazolinones as PARP14 inhibitors | PARP14, PARP15, PARP11 | PARP1 5/4885PARP2 10/4885PARP14 1/4885 |
| US-20230018702-A1 | QUINAZOLINONES AS PARP14 INHIBITORS | PARP14, PARP15, PARP11 | PARP1 5/4885PARP2 10/4885PARP14 1/4885 |
| US-20190194174-A1 | QUINAZOLINONES AS PARP14 INHIBITORS | PARP14, PARP15, PARP11 | PARP1 5/4885PARP2 10/4885PARP14 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.